Every Form 4 that ARS Pharmaceuticals, Inc. (SPRY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SPRY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRY filings page.
ARS Pharmaceuticals, Inc. President and CEO Donn Casale received a direct stock option award covering 1,036,923 Common Stock shares on October 1, 2026, with an exercise price of $4.12 per share. 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years. The option expires September 30, 2036.
ARS Pharmaceuticals, Inc. (SPRY) reported that Chief Commercial Officer Margaret Ekins Smith received a grant of stock options for 1,001,738 shares of common stock on September 1, 2026. The options have an exercise price of $5.77 per share and expire on August 31, 2036. According to the grant terms, 25% of the shares vest on August 17, 2027, with the remaining shares vesting monthly over the following three years. These options are held directly, and no Rule 10b5-1 trading plan is reported.
ARS Pharmaceuticals President Donn Casale received a large stock option grant tied to future service. The award covers 898,456 options to buy Common Stock at an exercise price of $7.96 per share, expiring on June 30, 2036. Following this grant, Casale holds 898,456 options directly. Vesting is long-term: 25% of the shares vest on June 1, 2027, with the remaining options vesting monthly over the next three years, encouraging retention and alignment with shareholders.
ARS Pharmaceuticals reported that an entity associated with RA Capital received a grant of stock options linked to its common stock. The award covers 30,000 options with an exercise price of $10.54 per share and expires on June 23, 2036.
These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. According to the disclosure, Dr. Peter Kolchinsky holds the option for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P., and any net proceeds reduce advisory fees owed to RA Capital Management, L.P. The reporting persons disclaim beneficial ownership except for any pecuniary interest.
ARS Pharmaceuticals director Rajeev Dadoo received a new stock option grant. He was awarded options covering 30,000 shares of common stock at an exercise price of $10.54 per share, expiring on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
ARS Pharmaceuticals director Pratik Shah received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. According to the terms, all 30,000 options will vest on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
This is a compensation-related award reported as an acquisition, with no open‑market buying or selling of ARS Pharmaceuticals shares disclosed in this filing.
ARS Pharmaceuticals director Kelly Michael received a stock option grant for 30,000 shares of common stock at an exercise price of $10.54 per share. The option expires on June 23, 2036 and will vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
ARS Pharmaceuticals director Saqib Islam received a stock option grant covering 30,000 shares of Common Stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Islam holds 30,000 stock options directly.
ARS Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Under an agreement, the economic benefit from any securities issued under these options must be transferred to OrbiMed-related entities.
ARS Pharmaceuticals director Brent L. Saunders received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders.
ARS Pharmaceuticals director Phillip M. Schneider received a grant of stock options as compensation. On June 24, 2026, he was awarded options covering 30,000 shares of common stock with an exercise price of $10.54 per share. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting and expire on June 23, 2036. After this grant, Schneider holds 30,000 stock options directly, and the transaction does not involve any open-market buying or selling of shares.
ARS Pharmaceuticals director Laura Shawver received a new stock option grant, not an open-market trade. The Form 4 shows an award of options to acquire 30,000 shares of common stock at an exercise price of $10.54 per share. Following this grant, she holds 30,000 stock options directly. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting, according to the footnote. The options expire on June 23, 2036, giving a long exercise window tied to her board service.
ARS Pharmaceuticals Chief Commercial Officer Eric Karas exercised stock options and sold shares in a planned transaction. He exercised options to acquire 25,000 shares of common stock at $1.50 per share, then sold 25,000 shares at $10.00 per share in an open-market sale.
The sale was made under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating it was pre-arranged. After these transactions, Karas directly holds 12,176 common shares, which include 1,861 shares acquired through the company’s 2020 Employee Stock Purchase Plan.
ARS Pharmaceuticals Chief Legal Officer Alexander A. Fitzpatrick reported an open-market sale of 3,355 shares of common stock at $10.00 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025 and leaves him holding 90,910 shares directly.
ARS Pharmaceuticals (SPRY) chief operating officer reports option exercise and share sale. On 11/13/2025, the officer exercised a stock option for 21,828 shares of common stock at an exercise price of $0.64 per share and then sold 21,828 shares of common stock the same day at a weighted average price of $8.7067 per share. Following these transactions, the officer directly held 10,789 shares of ARS Pharmaceuticals common stock. The reported holdings include shares previously acquired under the company’s 2020 Employee Stock Purchase Plan on December 31, 2024 and June 30, 2025.
ARS Pharmaceuticals, Inc. (SPRY) reported an insider transaction by its Chief Business Officer on a Form 4. On 11/12/2025, the officer exercised a stock option for 30,000 shares of common stock at an exercise price of $0.84 per share and then sold 30,000 shares at a weighted average price of $8.9119. The officer also sold an additional 136,380 shares of common stock at a weighted average price of $8.8634. Following these transactions, the officer reported 0 shares of common stock directly owned and 89,047 stock options beneficially owned.